GeoVax's GEO-CM04S1 Shows Promising Immune Response in CLL Patients at EHA 2025

The upcoming presentation at the European Hematology Association (EHA) 2025 Hybrid Congress by GeoVax Labs, Inc. marks a significant milestone in the fight against COVID-19, especially for immunocompromised individuals. The data to be presented focuses on the GEO-CM04S1 vaccine, a next-generation COVID-19 multi-antigen vaccine candidate, which has shown a superior cellular immune response compared to an authorized mRNA-based COVID-19 vaccine in patients with chronic lymphocytic leukemia (CLL). This population is known to have suboptimal protective responses to COVID-19 and other vaccines due to immune dysfunction.

The findings from the Phase II randomized clinical trial underscore the clinical potential of the GeoVax MVA multi-antigen platform. The GEO-CM04S1 vaccine, designed using a synthetic Modified Vaccinia Ankara (MVA) vector platform, expresses both spike (S) and nucleocapsid (N) antigens of SARS-CoV-2. This design aims to provide broader and more durable immune protection, a critical need for immunocompromised individuals who may not respond adequately to current vaccines.

The presentation by Dr. Alexey V. Danilov at the EHA 2025 Congress will highlight these initial results, offering hope for a more effective vaccination strategy for CLL patients and potentially other immunocompromised groups. The significance of this development cannot be overstated, as it addresses a real-world need for populations that remain vulnerable despite the availability of current COVID-19 vaccines. The data not only showcases the innovative approach of GeoVax but also opens new avenues for research and development in vaccine technology, particularly for those with compromised immune systems.

As the world continues to grapple with the challenges posed by COVID-19 and its variants, the importance of developing vaccines that can offer protection to all segments of the population, including the most vulnerable, is paramount. The GeoVax GEO-CM04S1 vaccine represents a promising step forward in this ongoing effort, with the potential to significantly impact public health strategies and vaccine development protocols moving forward.